12 235

Cited 0 times in

Novel Programmed Cell Death for Cancer Therapy

DC Field Value Language
dc.contributor.authorKoo, Gi-Bang-
dc.contributor.authorKim, Woo-Jung-
dc.contributor.authorKim, You-Sun-
dc.date.accessioned2015-08-31T06:44:30Z-
dc.date.available2015-08-31T06:44:30Z-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/11693-
dc.description.abstractReceptor-interacting protein kinase-3 (RIP3, or RIPK3) is an essential part of the cellular machinery that executes “programmed”, or “regulated”, necrosis. Here we show that programmed necrosis is activated in response to many chemotherapeutic agents and contributes to chemotherapy-induced cell death. However, we show RIP3 expression is often silenced in cancer cells due to genomic methylation near its transcriptional start site, so RIP3-dependent activation of MLKL and downstream programmed necrosis during chemotherapeutic death is largely repressed. Nevertheless, treatment with hypomethylating agents restores RIP3 expression, and thereby promotes sensitivity to chemotherapeutics in a RIP3-dependent manner. RIP3 expression is reduced in tumors when compared to normal tissue in 85% of breast cancer patients, suggesting that RIP3 deficiency is selected for during tumor growth/development. Since hypomethylating agents are reasonably well-tolerated in patients, we propose that RIP3-deficient cancer patients may benefit from receiving hypomethylating agents to induce RIP3 expression prior to treatment with conventional chemotherapeutics.-
dc.language.isoen-
dc.titleNovel Programmed Cell Death for Cancer Therapy-
dc.typeOther-
dc.type.localPoster-
Appears in Collections:
Others > Poster > Poster

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse